These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8069594)

  • 1. Control of in vivo fate of albumin derivatives utilizing combined chemical modification.
    Fujita T; Nishikawa M; Ohtsubo Y; Ohno J; Takakura Y; Sezaki H; Hashida M
    J Drug Target; 1994; 2(2):157-65. PubMed ID: 8069594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery.
    Lu W; Zhang Y; Tan YZ; Hu KL; Jiang XG; Fu SK
    J Control Release; 2005 Oct; 107(3):428-48. PubMed ID: 16176844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of mannosylated bovine serum albumin as a liver cell-specific carrier: quantitative comparison with other hepatotropic ligands.
    Ogawara K; Hasegawa S; Nishikawa M; Takakura Y; Hashida M
    J Drug Target; 1999; 6(5):349-60. PubMed ID: 10342383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives.
    Yabe Y; Nishikawa M; Tamada A; Takakura Y; Hashida M
    J Pharmacol Exp Ther; 1999 May; 289(2):1176-84. PubMed ID: 10215702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic disposition characteristics of 111In-labeled lactosaminated bovine serum albumin in rats.
    Nishida K; Eguchi Y; Takino T; Takakura Y; Hashida M; Sezaki H
    Pharm Res; 1991 Oct; 8(10):1253-7. PubMed ID: 1796043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
    Lu W; Wan J; She Z; Jiang X
    J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient scavenger receptor-mediated hepatic targeting of proteins by introduction of negative charges on the proteins by aconitylation: the influence of charge density and size of the proteins molecules.
    Yamasaki Y; Hisazumi J; Yamaoka K; Takakura Y
    Eur J Pharm Sci; 2003 Apr; 18(5):305-12. PubMed ID: 12694882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tyrosine and tryptophan in chemically modified serum albumin on its tissue distribution.
    Ma SF; Nishikawa M; Yabe Y; Yamashita F; Hashida M
    Biol Pharm Bull; 2006 Sep; 29(9):1926-30. PubMed ID: 16946511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein.
    Opanasopit P; Shirashi K; Nishikawa M; Yamashita F; Takakura Y; Hashida M
    Am J Physiol Gastrointest Liver Physiol; 2001 May; 280(5):G879-89. PubMed ID: 11292596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver.
    Nishida K; Mihara K; Takino T; Nakane S; Takakura Y; Hashida M; Sezaki H
    Pharm Res; 1991 Apr; 8(4):437-44. PubMed ID: 1714579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells.
    Opanasopit P; Nishikawa M; Yamashita F; Takakura Y; Hashida M
    J Drug Target; 2001; 9(5):341-51. PubMed ID: 11770704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells.
    Higuchi Y; Nishikawa M; Kawakami S; Yamashita F; Hashida M
    Int J Pharm; 2004 Dec; 287(1-2):147-54. PubMed ID: 15541921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice.
    Masuda H; Takakura Y; Hashida M
    Biochim Biophys Acta; 1999 Feb; 1426(3):420-8. PubMed ID: 10076058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
    Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
    J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives.
    Fujita T; Nishikawa M; Tamaki C; Takakura Y; Hashida M; Sezaki H
    J Pharmacol Exp Ther; 1992 Dec; 263(3):971-8. PubMed ID: 1469654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD36 is not involved in scavenger receptor-mediated endocytic uptake of glycolaldehyde- and methylglyoxal-modified proteins by liver endothelial cells.
    Nakajou K; Horiuchi S; Sakai M; Hirata K; Tanaka M; Takeya M; Kai T; Otagiri M
    J Biochem; 2005 May; 137(5):607-16. PubMed ID: 15944414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors.
    Yamasaki Y; Sumimoto K; Nishikawa M; Yamashita F; Yamaoka K; Hashida M; Takakura Y
    J Pharmacol Exp Ther; 2002 May; 301(2):467-77. PubMed ID: 11961045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of the receptor-mediated hepatic uptake of dextran in mice.
    Nishikawa M; Yamashita F; Takakura Y; Hashida M; Sezaki H
    J Pharm Pharmacol; 1992 May; 44(5):396-401. PubMed ID: 1279155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.
    Akamatsu K; Imai M; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
    J Drug Target; 1998; 6(3):229-39. PubMed ID: 9888309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of PEGylated serum albumin with multiple reduced thiols as a long-circulating scavenger of reactive oxygen species for the treatment of fulminant hepatic failure in mice.
    Katsumi H; Nishikawa M; Nishiyama K; Hirosaki R; Nagamine N; Okamoto H; Mizuguchi H; Kusamori K; Yasui H; Yamashita F; Hashida M; Sakane T; Yamamoto A
    Free Radic Biol Med; 2014 Apr; 69():318-23. PubMed ID: 24509159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.